Brookfield's CSquare data center IPO prices $300M below target
Private capital is still racing into data centers. The public market just flinched. Watch which one is early.
Brookfield-backed CSquare raised about $1.05 billion in its data center IPO this week, roughly $300 million below the target it marketed just days earlier. For developers and capital allocators, the shortfall is a useful crack of daylight: private money is still racing into data centers while the public market has started asking harder questions about the economics.
Why it matters
The buildout narrative has been one-directional, so a Brookfield-backed platform pricing below its own range is a data point worth logging. CSquare sold 50 million shares at $21, beneath the $23-to-$27 it had marketed, pegging its value near $3.25 billion instead of the roughly $4.2 billion it sought. Investors flagged that proceeds go almost entirely to repaying debt rather than funding growth, and that financing costs are outrunning revenue. We covered CSquare’s move to go public on July 7 when it was still targeting up to $1.35 billion; only by tracking the arc is the $300 million gap visible. The signal for developers is that the cost of data center capital is rising even as demand for the buildings stays hot, which will filter into how new campuses get underwritten and priced.
The numbers
CSquare posted a $66 million first-quarter loss on $270.5 million of revenue, and its shares slipped 1.57 percent on their first trading day after a late rally. The company, formed when Brookfield Infrastructure bought Cyxtera for $775 million and merged it with Evoque, operates more than 60 data center sites across the U.S., Canada and the U.K.
What’s next
Watch whether the tepid reception cools the pipeline of data center listings that had been forming, or whether it is read as a company-specific debt story rather than a sector verdict. Pair it with this week’s Palm Beach County denial of Project Tango: the buildout still faces both a siting test on the ground and a valuation test in the market. The megawatts are scarce; the patient capital may be getting scarcer too.